Update on quinolone-containing rescue therapies for Helicobacter pylori infection

Hideki Mori, Hidekazu Suzuki

Research output: Contribution to journalReview articlepeer-review

13 Citations (Scopus)


Third generation of quinolones, such as levofloxacin and moxifloxacin, - containing regimens are often used in second-line or rescue treatment of Helicobacter pylori infection. However, the increasing antibiotic resistance to quinolones affects the efficacies of quinolones-containing therapies in recent years. Therefore, there is a need to enhance the effectiveness of quinolonescontaining therapies. Sitafloxacin, a fourth-generation quinolone, and vonoprazan, a novel potassium-competitive acid blocker, are now available as more effective treatment options. The aim of this paper is to summarize the current evidence of quinolone-containing therapies in rescue treatments, and to discuss the importance of drug sensitivity tests or analysis of gyrA mutation before treatments.

Original languageEnglish
Pages (from-to)1733-1744
Number of pages12
JournalWorld Journal of Gastroenterology
Issue number15
Publication statusPublished - 2020 Apr 21
Externally publishedYes


  • Helicobacter pylori
  • Levofloxacin
  • Moxifloxacin
  • Sitafloxacin
  • Vonoprazan
  • gyrA

ASJC Scopus subject areas

  • Gastroenterology


Dive into the research topics of 'Update on quinolone-containing rescue therapies for Helicobacter pylori infection'. Together they form a unique fingerprint.

Cite this